Anzeige
Mehr »
Dienstag, 10.02.2026 - Börsentäglich über 12.000 News
Breaking News: Pacifica meldet neue hochgradige Entdeckung und genau deshalb kann der Markt das nicht ignorieren
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
677 Leser
Artikel bewerten:
(2)

Indica Labs and Molecular Instruments Announce Partnership to Advance AI-Powered Quantitative Image Analysis with HCR RNA-ISH

ALBUQUERQUE, NM and LOS ANGELES, CA / ACCESSWIRE / April 5, 2024 / Indica Labs, a leading provider of AI-powered digital pathology solutions, and Molecular Instruments® (MI), the inventor of the HCR Imaging technology, announce a new partnership to co-market compatibility between MI's patented HCR Imaging technology and Indica's HALO® software.

HCR RNA-ISH sets a new industry standard with its array of clinical-grade features including mild sample preparation with no protease digestion, native integration with existing IHC/IF workflows, preserving tissue and cell/nuclear morphology for high quality image analysis. By using HALO® modules, such as ISH, FISH, ISH-IHC, and FISH-IF, researchers will be able to analyze both chromogenic and fluorescent HCR RNA-ISH images and perform fast, AI-based quantitative analysis on whole slide images.

Indica Labs' industry-leading HALO and HALO AI software enables high-throughput, AI-based quantitative tissue analysis. HALO modules simplify the analysis workflow so there is no need to 'build' algorithms from scratch while generating expression data on a cell-by-cell basis. HALO Spatial Analysis and HALO AI deep learning classifiers are used in combination with any of the ISH modules to explore the distribution and spatial relationships between different cell phenotypes in the context of the tissue.

HCR RNA-ISH and IHC image from Molecular Instruments is shown at left. HALO and HALO AI image analysis markup is shown at right where RNA is shown in magenta, nuclei are shown in blue, and the HCR Membrane Stain (membrane localized protein biomarker) is shown in gray.

"We are excited to partner with MI to address the growing needs of our research customers for RNA-ISH assays that maintain cellular morphology," said Anne Hellebust, Director of Product, Life Sciences of Indica Labs. "Combining MI's HCR RNA-ISH technologies with our powerful AI-based analysis downstream enables us to provide a streamlined workflow for ISH staining and image analysis."

Dr. Aneesh Acharya, Chief Commercial Officer of Molecular Instruments, remarked "Building advanced tools that are accessible and easy to integrate into existing workflows is central to our mission at MI. Our partnership with Indica Labs symbolizes the dedication of both organizations to bringing state-of-the-art products to as many users as possible. We're thrilled that HCR Products are both compatible with all existing ISH analysis tools offered by HALO® and over time will enable novel analysis workflows previously considered impossible."

To learn more about the HCR Platform, please visit:

https://www.hcrimaging.com/

About Indica Labs

Indica Labs is the world's leading provider of AI-powered digital pathology software and services. Our flagship HALO® and HALO AI platform powers quantitative evaluation of digital pathology images. HALO Link facilitates research-focused image management and collaboration while HALO AP® delivers AI-powered diagnostics in a case-based platform. Through a commitment to open pathology and a combination of performance, scalability, and usability, our software solutions enable pharmaceutical companies, diagnostic labs, hospitals, research organizations, and Indica's own contract pharma services team to advance tissue-based research, clinical trials, and diagnostics.

About Molecular Instruments

Molecular Instruments® (MI) develops and synthesizes kits powered by its innovative HCR Platform for bioimaging applications in academic research, drug development, and clinical pathology and diagnostics. MI offers products for automated and manual chromogenic and fluorescence in situ hybridization (ISH) assays, featuring a protease-free workflow, native compatibility with existing IHC/IF assays, and straightforward image analysis. HCR Products are designed to be accessible to all researchers with complimentary introductory Starter Kits, free custom probe design, and pricing that makes sense.

Media contacts:

Indica Labs
Kate Lillard, PhD
kate@indicalab.com

Molecular Instruments
Joyce Yoo
joyce@molecularinstruments.com

SOURCE: Indica Labs



View the original press release on accesswire.com

© 2024 ACCESS Newswire
Favoritenwechsel
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.